Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere

NCT06900543 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

108

Enrollment

INDUSTRY

Sponsor class

Conditions

Unresectable Hepatocellular Carcinoma

Interventions

DRUG: NRT6003 Injection
DRUG: cTACE

Sponsor

Chengdu New Radiomedicine Technology Co. LTD.